Patents by Inventor Justus B. Cohen
Justus B. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11883448Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: GrantFiled: August 5, 2020Date of Patent: January 30, 2024Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Patent number: 11419926Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.Type: GrantFiled: May 20, 2019Date of Patent: August 23, 2022Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Publication number: 20210138007Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: ApplicationFiled: August 5, 2020Publication date: May 13, 2021Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Publication number: 20210121513Abstract: Provided herein are antigenically stealthed HSV particles, and methods of use of the antigenically-stealthed HSV particles.Type: ApplicationFiled: May 31, 2019Publication date: April 29, 2021Inventors: Joseph C. Glorioso, III, Gary H. Cohen, Doina Atanasiu, Tina Marie Cairns, Bonnie Lynn Hall, Justus B. Cohen, Ceren Tuzmen
-
Publication number: 20200147189Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.Type: ApplicationFiled: May 20, 2019Publication date: May 14, 2020Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Patent number: 10576115Abstract: The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.Type: GrantFiled: November 14, 2018Date of Patent: March 3, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Publication number: 20190262410Abstract: The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.Type: ApplicationFiled: November 14, 2018Publication date: August 29, 2019Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Patent number: 10328136Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.Type: GrantFiled: January 18, 2017Date of Patent: June 25, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Patent number: 10201575Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and a plurality of copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells, and a deletion of the internal repeat (joint) region in the HSV genome comprising one copy of the ICP0, ICP34.5, LAT, and ICP4 genes and the ICP47 promoter. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: GrantFiled: October 28, 2014Date of Patent: February 12, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Patent number: 10188686Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: GrantFiled: July 7, 2016Date of Patent: January 29, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Patent number: 10172893Abstract: The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.Type: GrantFiled: June 7, 2017Date of Patent: January 8, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Publication number: 20180148711Abstract: The present invention generally provides HSV-based genome editing vectors, cell-based compositions, and methods of using the same.Type: ApplicationFiled: May 27, 2016Publication date: May 31, 2018Inventors: Mitchell H. FINER, Kenneth P. GREENBERG, Justus B. COHEN, Joseph C. GLORIOSO, III
-
Publication number: 20170274025Abstract: The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.Type: ApplicationFiled: June 7, 2017Publication date: September 28, 2017Inventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Publication number: 20170189514Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.Type: ApplicationFiled: January 18, 2017Publication date: July 6, 2017Inventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Publication number: 20170107537Abstract: The present invention provides an HSV vector comprising an envelope comprising one or more mutant gB and/or gH envelope glycoproteins, whereby the HSV vector exhibits at least 25% increased rate-of-entry after 20 minutes when assayed at 30° C. or 37° C. in Vero cells after first incubating at 4° C. relative to a control HSV comprising wild-type gB and gH glycoproteins. The invention also provides a viral stock comprising the inventive HSV vector.Type: ApplicationFiled: April 25, 2016Publication date: April 20, 2017Inventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Patent number: 9593347Abstract: The invention provides modified HSV vectors that exhibit enhanced entry of cells, either through direct infection and/or lateral spread. In one aspect, HSV vectors of the present invention can directly infect cells through interaction with cell proteins other than typical mediators of HSV infection. In another aspect, the invention provides an HSV vector, which exhibits lateral spread in cells typically resistant to HSV lateral spread, such as cells lacking gD receptors. The invention further provides DNA encoding mutant forms of the HSV gB and gH glycoproteins, stocks of the inventive virus, and methods for effecting viral targeting and efficient entry of cells. The invention also pertains to the use of the inventive vectors for treating cancers.Type: GrantFiled: April 18, 2011Date of Patent: March 14, 2017Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
-
Publication number: 20170035819Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: ApplicationFiled: July 7, 2016Publication date: February 9, 2017Inventors: Hiroaki Uchida, Justus B. Cohen, Joseph C. Glorioso, III, Paola Grandi
-
Publication number: 20160250267Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.Type: ApplicationFiled: October 28, 2014Publication date: September 1, 2016Inventors: Hiroaki UCHIDA, Justus B. COHEN, Joseph C. GLORIOSO, III, Paola GRANDI
-
Publication number: 20130096186Abstract: The invention provides modified HSV vectors that exhibit enhanced entry of cells, either through direct infection and/or lateral spread. In one aspect, HSV vectors of the present invention can directly infect cells through interaction with cell proteins other than typical mediators of HSV infection. In another aspect, the invention provides an HSV vector, which exhibits lateral spread in cells typically resistant to HSV lateral spread, such as cells lacking gD receptors. The invention further provides DNA encoding mutant forms of the HSV gB and gH glycoproteins, stocks of the inventive virus, and methods for effecting viral targeting and efficient entry of cells. The invention also pertains to the use of the inventive vectors for treating cancers.Type: ApplicationFiled: April 18, 2011Publication date: April 18, 2013Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen